-+ 0.00%
-+ 0.00%
-+ 0.00%

Genprex partners with US-based CDMO to scale up manufacturing for diabetes gene therapy program

PUBT·08/18/2026 11:03:50
Listen to the news
Genprex partners with US-based CDMO to scale up manufacturing for diabetes gene therapy program
  • Genprex entered a development and manufacturing agreement with a U.S.-based CDMO to scale up its diabetes gene therapy manufacturing.
  • Partnership targets a shift from research-grade output to clinical- and commercial-ready supply in a cGMP facility.
  • CDMO to produce drug product for IND-enabling preclinical studies, then supply future clinical trials.
  • Program uses an AAV vector to deliver Pdx1 and MafA genes to the pancreas via the pancreatic duct.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genprex Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-028250), on August 18, 2026, and is solely responsible for the information contained therein.